about
Pulmonary Tuberculosis Diagnosis: Where We Are?Toll-Like Receptors in the Pathogenesis of Autoimmune DiseasesPhage display as a promising approach for vaccine developmentThe insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.Role of oral microbiome on oral cancers, a review.CAR-modified T-cell therapy for cancer: an updated review.Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragments.Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor.Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies.Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique.Selection of single chain antibody fragments binding to the extracellular domain of 4-1BB receptor by phage display technology.Survey of the Antibiofilm and Antimicrobial Effects of Zingiber officinale (in Vitro Study)CTX-M extended-spectrum β-lactamase-producing Klebsiella spp, Salmonella spp, Shigella spp and Escherichia coli isolates in Iranian hospitals.Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.Immunotherapeutic approaches for cancer therapy: An updated review.The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.Current methods for the identification of carbapenemases.Myeloid-derived suppressor cells in B cell malignancies.MicroRNA-induced drug resistance in gastric cancer.IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis.The immunobiology of myeloid-derived suppressor cells in cancer.Nanoparticles: Novel vehicles in treatment of Glioblastoma.Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions.Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.The role of oncomirs in the pathogenesis and treatment of breast cancer.Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line.Application of arteether-loaded polyurethane nanomicelles to induce immune response in breast cancer model.The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis.The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231).Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.Utilization of nanoparticle technology in rheumatoid arthritis treatment.Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.IGF1R and c-met as therapeutic targets for colorectal cancer.Application of nanoparticle technology in the treatment of Systemic lupus erythematous.
P50
Q26739001-C377B638-0D50-4FD3-BCE7-7E80B1D8975AQ26770257-5D889B24-34AF-4967-8E68-B89750194D6CQ28074592-AE793089-C121-4878-8A5D-B3DABFDABF20Q30244095-208D3586-1FC5-4D73-9620-2342077C5A9EQ30244940-4BB6E68D-9F28-4449-8878-9EECE7401BD8Q34044213-36F0101D-8880-4E5B-BD1F-15E2875808B5Q34290711-38D6A51B-3449-43DA-B1C4-7A9CA5DDE1BEQ36089851-F3CDB9FD-E7DE-443B-8B5E-0C993838C30EQ36136323-13576907-D103-4FD7-88C3-9AA5DCDD5310Q36193805-69183FA0-DC93-4625-BAB4-F211EA0C2ABCQ36241772-9B49EA9D-0C3E-47F8-A8F8-2A20400A1611Q36250366-A1141CEB-C935-4F1D-B614-E4985AB32543Q36262284-11A803F0-423B-485E-B06C-0290CD05D6AFQ36324254-75D85754-C7EB-4E38-9557-4CBD4F63F76AQ36828785-83313919-F125-46E3-8CFD-D32695D16648Q37053548-582F2B1D-A5FA-4A9E-AAD7-1DE0EA6FE134Q38321754-87197CE8-91BB-4548-95A0-11095796C483Q38328927-BE25BB4F-6D88-457A-850B-B1DD211EC401Q38388102-FD6F3538-6D88-4570-AFFB-727E3E6C2172Q38473746-D3B71743-A8F5-4F97-B90C-C41CE58604F2Q38542764-8D906AF9-F7C1-4DCC-97BA-5A783C5A7DB3Q38563315-1811DDE3-2D84-4CB5-A262-8F00F45D7EDFQ38578686-7A9DBD50-980E-4F6E-9138-054DFCF1170CQ38582985-9DA1DAF9-5C2F-4708-BCB0-D1F999F0EBB4Q38617794-A00A2162-7E5C-4882-9390-3959DAAC3EEDQ38649547-76CB1DE5-07D5-4F19-ADEF-C5398BAD9DD2Q38706430-8F8F5238-FE61-4CFC-9C60-38F2B5901A44Q38709499-1924E77D-FA00-4DE4-A293-327733487374Q38711262-3B7BAC03-3D0D-4BC3-82C0-72812A0D22DFQ38738831-C2FC246C-1D66-4A22-B662-EE7AE95B26D6Q38742634-38A71651-F3CE-4A24-8C07-23DD45FDFFB1Q38761421-ED078D84-CD5E-4F89-A411-5C2A9DA3B6FCQ38766425-FCF75D7F-7CDA-4B0B-9BEA-66188644B3BDQ38767477-20BA1271-7AC4-43F5-BA72-AEC85F4AC92CQ38770342-D6E72397-3B82-4257-9BD6-D60842238D74Q38806325-38C62160-C8DB-49F5-A3A2-272942143963Q38822193-97968B8E-442F-4C25-BA8A-4DEB3EB06AB8Q38896543-0CDB2ECA-D557-46AF-8534-D820E453E14FQ38911985-996E301F-EF0A-42E2-AA2A-A35C5DD25E28Q38934611-F9D8B70C-E391-4CED-83F0-0F5021B55055
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Mehdi Yousefi
@ast
Mehdi Yousefi
@en
Mehdi Yousefi
@es
Mehdi Yousefi
@sl
type
label
Mehdi Yousefi
@ast
Mehdi Yousefi
@en
Mehdi Yousefi
@es
Mehdi Yousefi
@sl
prefLabel
Mehdi Yousefi
@ast
Mehdi Yousefi
@en
Mehdi Yousefi
@es
Mehdi Yousefi
@sl
P106
P1153
16235087000
P21
P214
74151776793618011889
P31
P496
0000-0003-0099-6728
P734
P735
P7859
viaf-74151776793618011889